Navigation Links
FDA Panel Gives Blessing to New Weight-Loss Drug

THURSDAY, May 10 (HealthDay News) -- An advisory panel to the U.S. Food and Drug Administration on Thursday recommended approval of the weight-loss medication lorcaserin, even though concerns remain about cardiovascular side effects.

If the agency were to give the nod to the drug, lorcaserin would become the first new weight-loss pill made available to Americans in a decade. The FDA is not bound to follow the advice of its expert panels, but it typically does.

The panel of experts voted 18 to 4, with one abstention, for approval, saying the drug's benefits "outweigh the potential risks when used long term" for people battling excess weight, the Associated Press reported.

Lorcaserin has not always received such a favorable reception. According to the AP, in 2010 scientists voiced concern that the drug might come with health risks, citing tumors that had developed in animal testing involving the drug.

However, Arena Pharmaceuticals, the San Francisco-based company that makes lorcaserin, has since submitted additional data in hopes the FDA might look more favorably on the drug.

According to a review of the available research posted by FDA staff online on Tuesday, that new data suggests that lorcaserin carries only a "negligible risk" of cancer in humans, the AP said. But concerns over the potential for cardiovascular risks -- hypertension in people with diabetes, for example, or injury to heart valves -- remain.

According to the AP, lorcaserin is one of three experimental weight-loss drugs that the FDA is taking a second look at after first saying no to the medications in 2010 or early 2011 because of concerns about significant side effects.

In February, another new weight-loss drug, Qnexa, was endorsed by an FDA advisory panel. The agency is expected to make a final decision on Qnexa in July.

More information

Find out more about healthy weight loss at the U.S. Centers for Disease Control and Prevention.

-- E.J. Mundell

SOURCE: Associated Press

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. U.S. Panel Rejects Ovarian Cancer Screening
2. Panel of serum biomarkers may reduce number of lung biopsies needed
3. FDA Panel Cites Clot Risk From Contraceptive Patch
4. Panel endorses active monitoring and delay of treatment for low-risk prostate cancer
5. Expert Panel Pinpoints Environmental Culprits in Breast Cancer
6. FDA Panels to Weigh Safety of Newer Forms of the Pill
7. Panel of melanoma mutations opens door to new treatment possibilities
8. Many on Medical Guideline Panels Have Conflicts of Interest: Study
9. Panels Rejection of PSA Test Spurs Mixed Reaction From Experts
10. Osteoporosis Drugs Safety Subject of FDA Panel
11. U.S. Panel Recommends Free Coverage of Birth Control
Post Your Comments:
Related Image:
FDA Panel Gives Blessing to New Weight-Loss Drug 
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology: